Split dosing GLP-1s: TikTok trend or legitimate strategy?

What did @whambamjammy actually say?

The creator walks through a specific self-dosing method for compounded tirzepatide. They draw 50 units total for a 5 mg dose, inject 25 units, then inject the remaining 25 units three days later. They also mention an app called Shotsy to track injections and milligrams. That's the whole claim: splitting one weekly dose into two smaller injections spaced three days apart, based on personal experience with PCOS-related weight management.

To be clear, this is not a protocol from a prescriber. The creator frames it as "this is what I do," not medical advice. But with 5,200 views and a PCOS hashtag, the practical effect is that it functions as a dosing tutorial for a prescription drug, which deserves scrutiny.

Does the science back this up?

Partially, but the pharmacology here is more complicated than the video suggests. Tirzepatide has a half-life of approximately five days, which is why it's designed as a once-weekly injection. Splitting that dose does not violate basic pharmacology, but it also is not validated in any clinical trial as an equivalent or superior approach.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) established tirzepatide's efficacy on a once-weekly schedule at fixed doses. No sub-study examined split dosing for tolerability or outcomes. The rationale some patients use for splitting, reducing GI side effects by flattening the peak concentration, has some theoretical basis. A higher peak Cmax can correlate with nausea in GLP-1 receptor agonist users (Htike et al., 2017, Diabetes, Obesity and Metabolism), but tirzepatide's five-day half-life means the Cmax reduction from splitting three days apart is likely modest at best. This is not a well-studied strategy, and calling it a reliable tolerability hack would be an overreach.

What did they get wrong (or right)?

They got the unit math right for their specific concentration. If 5 mg equals 50 units in their vial, then 25 units is half the dose. That's basic arithmetic, and it checks out, assuming their vial concentration is accurate, which brings up the bigger issue: compounded tirzepatide concentrations are not standardized. Different compounding pharmacies produce different concentrations, and unit-based dosing described in this video cannot be generalized to someone else's vial without knowing the exact mg/mL concentration. Applying this video's unit math to a different concentration could result in a significant over- or underdose.

The three-day interval is presented without any clinical rationale. It sounds intuitively logical, but the creator does not explain why three days specifically. There is no published protocol supporting this interval as optimal for splitting tirzepatide.

What should you actually know?

Split dosing of GLP-1 receptor agonists is something patients do, and some prescribers do informally discuss it for tolerability, but it is not FDA-approved dosing and it is not covered by any prescribing guidelines for Zepbound or Mounjaro. If you are using compounded tirzepatide and struggling with side effects, that conversation belongs with your prescriber, not a TikTok comment section.

The Shotsy app is a real tool that some GLP-1 users find helpful for tracking doses and timing. Using a tracking app is reasonable. But an app cannot verify your vial's concentration, confirm your dose is appropriate for your body weight or health status, or flag drug interactions. It is a reminder tool, not a clinical safeguard.

One more thing worth saying directly: compounded tirzepatide is not the same product as Zepbound. The FDA has raised concerns about compounded GLP-1 medications, including questions about purity, concentration accuracy, and sterility. Anyone using compounded peptides should source them through a licensed compounding pharmacy with a valid prescription and ideally 503B outsourcing facility status.

Bottom line

The creator is describing a real practice that some patients use and some clinicians loosely tolerate. They're not inventing something dangerous out of thin air. But the unit-based dosing tutorial is the problem: what works in their vial at their concentration does not translate to the next person's vial. The lack of any clinical sourcing for the three-day split interval is also notable. Credit for transparency about what they're doing, but this is not a protocol anyone should adopt without talking to their prescriber first.